Key result
PI3K/p110α inhibition selectively delayed arterial thrombosis and inhibited neointima formation without affecting re-endothelialization following vascular injury in a murine model.
Why the study?
Does PI3K/p110α inhibition reduce arterial thrombosis and neointima formation without impairing re-endothelialization in vascular injury models?
Does PI3K/p110α inhibition reduce arterial thrombosis and neointima formation without impairing re-endothelialization in vascular injury models?
PI3K/p110α inhibition selectively prevents arterial thrombosis and neointima formation while sparing re-endothelialization, highlighting its potential as a novel target for drug-eluting stents.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for selective PI3K/p110α inhibition in vascular injury; leaves open translation to human stent applications.
BACKGROUND: Impaired re-endothelialization and stent thrombosis are a safety concern associated with drug-eluting stents (DES). PI3K/p110α controls cellular wound healing pathways, thereby representing an emerging drug target to modulate vascular homoeostasis after injury. METHODS AND RESULTS: PI3K/p110α was inhibited by treatment with the small molecule inhibitor PIK75 or a specific siRNA. Arterial thrombosis, neointima formation, and re-endothelialization were studied in a murine carotid artery injury model. Proliferation and migration of human vascular smooth muscle cell (VSMC) and endothelial cell (EC) were assessed by cell number and Boyden chamber, respectively. Endothelial senescence was evaluated by the β-galactosidase assay, endothelial dysfunction by organ chambers for isometric tension. Arterial thrombus formation was delayed in mice treated with PIK75 when compared with controls. PIK75 impaired arterial expression and activity of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1); in contrast, plasma clotting and platelet aggregation did not differ. In VSMC and EC, PIK75 inhibited expression and activity of TF and PAI-1. These effects occurred at the transcriptional level via the RhoA signalling cascade and the transcription factor NFkB. Furthermore, inhibition of PI3K/p110α with PIK75 or a specific siRNA selectively impaired proliferation and migration of VSMC while sparing EC completely. Treatment with PIK75 did not induce endothelial senescence nor inhibit endothelium-dependent relaxations. In line with this observation, treatment with PIK75 selectively inhibited neointima formation without affecting re-endothelialization following vascular injury. CONCLUSION: Following vascular injury, PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization. Hence, PI3K/p110α represents an attractive new target in DES design.
No takes yet. Share an insight, caveat, or question.
Holy et al. (2013) studied Vascular injury. PI3K/p110α inhibition (PIK75 or siRNA) vs. Controls was evaluated on Arterial thrombosis, neointima formation, and re-endothelialization. PI3K/p110α inhibition selectively delayed arterial thrombosis and inhibited neointima formation without affecting re-endothelialization following vascular injury in a murine model.
Synapse has enriched 10 related papers. Consider them for comparative context: